Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biopharmaceutical company developing innovative fibrosis-focused therapies, has successfully closed a public offering, raising approximately $23 million in ...

AccuWeather says that the Central American Gyre could form around mid-May, potentially laying the groundwork for a tropical ...

Jefferies acted as lead book-running manager for the offering and H.C. Wainwright & Co. acted as co-manager for the offering. Gyre intends to use the net proceeds from this offering, together with its ...

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biopharmaceutical company developing innovative fibrosis-focused therapies, has successfully closed a public offering, raising approximately $23 million in ...

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies ...

The Central American Gyre is the name of a broad area of slow-spinning low pressure that forms seasonally over the eastern Pacific Ocean and overlapping with the western Caribbean Sea. AccuWeather ...

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that it ...

Gyre Therapeutics, a biotechnology company focused on organ fibrosis, has announced an underwritten public offering of its common stock, which may include additional shares for underwriters at the ...